Marizyme, Inc. (MRZM)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -34.28 Million USD | -78.48% |
| 2022 | -34.53 Million USD | -3.53% |
| 2021 | -10.82 Million USD | -95.17% |
| 2020 | -5.2 Million USD | -392.24% |
| 2019 | - USD | -328.13% |
| 2018 | -248.73 Thousand USD | -97.84% |
| 2017 | -124.91 Thousand USD | 31.3% |
| 2016 | 48.18 Thousand USD | 81.07% |
| 2015 | -960.69 Thousand USD | 14.71% |
| 2014 | -1.12 Million USD | 47.67% |
| 2013 | -2.15 Million USD | 64.84% |
| 2012 | - USD | -447.96% |
| 2011 | -10.25 Million USD | 9884.72% |
| 2010 | 4.15 Million USD | 6.65% |
| 2009 | -19.26 Thousand USD | 80.28% |
| 2008 | -19.26 Thousand USD | -195.35% |
| 2007 | -97.66 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.36 Million USD | 50.86% |
| 2024 Q1 | -1.16 Million USD | 0.19% |
| 2023 Q2 | -6.25 Million USD | -867.8% |
| 2023 Q3 | -8.62 Million USD | -37.79% |
| 2023 Q4 | -7.83 Million USD | 9.18% |
| 2023 Q1 | -646.54 Thousand USD | 97.09% |
| 2023 FY | - USD | -78.48% |
| 2022 FY | - USD | -3.53% |
| 2022 Q2 | -6.18 Million USD | -10.12% |
| 2022 Q1 | -5.61 Million USD | -5.08% |
| 2022 Q3 | -531.67 Thousand USD | 91.4% |
| 2022 Q4 | -22.2 Million USD | -4076.41% |
| 2021 Q4 | -5.34 Million USD | -242.15% |
| 2021 FY | - USD | -95.17% |
| 2021 Q1 | -2.39 Million USD | 7.19% |
| 2021 Q2 | -2.16 Million USD | 9.71% |
| 2021 Q3 | -1.56 Million USD | 27.74% |
| 2020 Q1 | -471.37 Thousand USD | -93.58% |
| 2020 Q4 | -2.57 Million USD | -24.91% |
| 2020 Q3 | -2.06 Million USD | -374.82% |
| 2020 Q2 | -434.91 Thousand USD | 7.73% |
| 2020 FY | - USD | -392.24% |
| 2019 FY | - USD | -328.13% |
| 2019 Q4 | -243.49 Thousand USD | 52.12% |
| 2019 Q1 | -67.54 Thousand USD | -7.92% |
| 2019 Q2 | -237.36 Thousand USD | -251.41% |
| 2019 Q3 | -508.56 Thousand USD | -114.26% |
| 2018 Q3 | -70.62 Thousand USD | -2.74% |
| 2018 Q1 | -45.18 Thousand USD | 76.38% |
| 2018 FY | - USD | -97.84% |
| 2018 Q4 | -62.59 Thousand USD | 11.37% |
| 2018 Q2 | -68.73 Thousand USD | -52.14% |
| 2017 FY | - USD | 31.3% |
| 2017 Q3 | 39.57 Thousand USD | 139.26% |
| 2017 Q4 | -191.25 Thousand USD | -583.23% |
| 2017 Q2 | 16.54 Thousand USD | -31.53% |
| 2017 Q1 | 24.15 Thousand USD | 103.14% |
| 2016 FY | - USD | 81.07% |
| 2016 Q4 | -770 Thousand USD | -3750.0% |
| 2016 Q1 | -70 Thousand USD | 0.0% |
| 2016 Q3 | -20 Thousand USD | 0.0% |
| 2016 Q2 | -20 Thousand USD | 71.43% |
| 2015 FY | - USD | 14.71% |
| 2014 FY | - USD | 47.67% |
| 2013 Q3 | 817.69 Thousand USD | 3863.33% |
| 2013 Q2 | -21.72 Thousand USD | 94.77% |
| 2013 Q1 | -415.74 Thousand USD | 86.63% |
| 2013 Q4 | 265.18 Thousand USD | -67.57% |
| 2013 FY | - USD | 64.84% |
| 2012 Q3 | -1.8 Million USD | -24.79% |
| 2012 FY | - USD | -447.96% |
| 2012 Q4 | -3.1 Million USD | -72.21% |
| 2012 Q2 | -1.44 Million USD | -496.54% |
| 2012 Q1 | -242.55 Thousand USD | 81.88% |
| 2011 Q2 | -1.23 Million USD | 38.85% |
| 2011 Q1 | -2.02 Million USD | -940.33% |
| 2011 Q3 | -1.45 Million USD | -17.35% |
| 2011 FY | - USD | 9884.72% |
| 2011 Q4 | -1.33 Million USD | 7.77% |
| 2010 Q1 | -2079.00 USD | -126.22% |
| 2010 FY | - USD | 6.65% |
| 2010 Q4 | -194.41 Thousand USD | -1103.8% |
| 2010 Q3 | -16.15 Thousand USD | 69.65% |
| 2010 Q2 | -53.2 Thousand USD | -2459.31% |
| 2009 FY | - USD | 80.28% |
| 2009 Q1 | 17.59 Thousand USD | 299.46% |
| 2009 Q2 | -6915.00 USD | -139.3% |
| 2009 Q4 | -919.00 USD | 96.89% |
| 2009 Q3 | -29.59 Thousand USD | -327.98% |
| 2008 Q4 | -8822.00 USD | 61.5% |
| 2008 FY | - USD | -195.35% |
| 2008 Q1 | -27.34 Thousand USD | 3.58% |
| 2008 Q2 | -13.73 Thousand USD | 49.78% |
| 2008 Q3 | -22.91 Thousand USD | -66.88% |
| 2007 Q4 | -28.35 Thousand USD | -42.37% |
| 2007 Q1 | -10 Thousand USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | -21.62 Thousand USD | -116.27% |
| 2007 Q3 | -19.91 Thousand USD | 7.9% |
| 2006 Q4 | -10 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 51.741% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -478.209% |
| SQZ Biotechnologies Company | -64.14 Million USD | 46.553% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -97.36% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 136.455% |
| Mesoblast Limited | -62.38 Million USD | 45.053% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2131.795% |
| Genus plc | 73.7 Million USD | 146.515% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -418.511% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -866.493% |
| ContraFect Corporation | -64.99 Million USD | 47.258% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -290.806% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -657.402% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2345.518% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1196.356% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -1375.221% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -6517.457% |
| Accustem Sciences Inc. | -3.74 Million USD | -815.046% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 28.916% |
| EV Biologics, Inc. | -1.26 Million USD | -2605.438% |
| Q BioMed Inc. | -617.62 Thousand USD | -5450.505% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1059.728% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -5320.801% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1400.619% |
| Biomind Labs Inc. | -1.03 Million USD | -3213.663% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 447.084% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -378.706% |
| Skye Bioscience, Inc. | -13.54 Million USD | -153.046% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -2204.773% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -137025.884% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -782.56% |
| IMV Inc. | -35.52 Million USD | 3.496% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -116.018% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1270.184% |
| GB Sciences, Inc. | -1.41 Million USD | -2314.384% |
| Alpha Cognition Inc. | -9.7 Million USD | -253.213% |
| HST Global, Inc. | -5303.00 USD | -646354.29% |
| CSL Limited | 4.78 Billion USD | 100.716% |
| Halberd Corporation | -74.27 Thousand USD | -46052.305% |
| Enzolytics Inc. | -2.12 Million USD | -1515.504% |
| Resverlogix Corp. | -11.74 Million USD | -191.956% |
| Affymax, Inc. | -14.29 Million USD | -139.814% |
| SYBLEU INC | -141.57 Thousand USD | -24115.038% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1019.206% |
| argenx SE | -216.02 Million USD | 84.131% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 38.052% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 2916.883% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -2187.099% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 9148.968% |
| AVAX Technologies, Inc. | -6.11 Million USD | -460.829% |
| Zenith Capital Corp. | -8.6 Million USD | -298.344% |
| Genscript Biotech Corporation | -248.71 Million USD | 86.217% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -196682.452% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1301.268% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -19375.413% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 13.511% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1085.256% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -3176.41% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 509937.463% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1858.942% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -1684.647% |
| BioStem Technologies, Inc. | -7.55 Million USD | -353.84% |
| ONE Bio Corp. | 13.61 Million USD | 351.828% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -18830.835% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -1566.576% |
| Agentix Corp. | -1.37 Million USD | -2399.094% |
| LadRx Corporation | 412.28 Thousand USD | 8415.034% |
| Cell Source, Inc. | -4.27 Million USD | -702.37% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -9235.379% |
| Regen BioPharma, Inc. | 1.46 Million USD | 2438.506% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -3558.841% |
| NovAccess Global Inc. | -1.03 Million USD | -3212.869% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 487.195% |
| Itoco Inc. | -1.86 Million USD | -1734.22% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -8930.47% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -2971.816% |
| Kadimastem Ltd | -2.62 Million USD | -1206.269% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -14234.715% |
| CytoDyn Inc. | -18.02 Million USD | -90.146% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -43278.343% |
| Mobile Lads Corp. | -2.24 Million USD | -1429.631% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -280229.307% |
| Qrons Inc. | -40.08 Thousand USD | -85430.478% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -6958.477% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 6599.683% |
| Rebus Holdings, Inc. | -951 Thousand USD | -3504.781% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -3127.98% |
| International Stem Cell Corporation | 202 Thousand USD | 17071.025% |
| Bioxytran, Inc. | -3.82 Million USD | -797.386% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -65024.375% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1292.462% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 4.426% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -76081.047% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1152.062% |
| Neutra Corp. | -181.24 Thousand USD | -18814.228% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -70.055% |
| PureTech Health plc | -11.62 Million USD | -194.844% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -70.067% |
| IXICO plc | -707 Thousand USD | -4748.864% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -346.083% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 29.091% |
| CSL Limited | 4.73 Billion USD | 100.724% |
| Cellectis S.A. | -92.63 Million USD | 62.993% |